Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 12, 2006, Pages 3310-3314

  Parks, Daniel J ^a   LaFrance, Louis V ^a   Calvo, Raul R ^a   Milkiewicz, Karen L ^a   José Marugán, Juan ^a   Raboisson, Pierre ^a   Schubert, Carsten ^a   Koblish, Holly K ^a   Zhao, Shuyuan ^a   Franks, Carol F ^a   Lattanze, Jennifer ^a   Carver, Theodore E ^a   Cummings, Maxwell D ^a   Maguire, Diane ^a   Grasberger, Bruce L ^a   Maroney, Anna C ^a   Lu, Tianbao ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

HDM2; HDM2 antagonist; p53; Pharmacokinetic; Protein protein interaction; Structure based drug design

Indexed keywords

1,4 BENZODIAZEPINE 2,5 DIONE ANTAGONIST; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; PROTEIN; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG; BENZODIAZEPINE DERIVATIVE; BZ 423; BZ-423; MDM2 PROTEIN, HUMAN; VALERIC ACID DERIVATIVE;

ALKYLATION; ARTICLE; BIOAVAILABILITY; CANCER CELL CULTURE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; ANIMAL; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MOUSE; PROTEIN BINDING; SYNTHESIS; TUMOR CELL LINE; X RAY CRYSTALLOGRAPHY;

ALKYLATION; ANIMALS; BENZODIAZEPINES; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PENTANOIC ACIDS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33747126523     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.03.055     Document Type: Article

References (15)

1. Harris S.L., and Levine A.J. Oncogene 24 (2005) 2899
2. Cao C., Shinohara E.T., Niermann K.J., Donnelly E.F., Chen X., Hallahan D.E., and Lu B. Mol. Cancer Ther. 4 (2005) 1137
3. Chène P. Mol. Cancer Res. 2 (2004) 20
4. Zheleva D.I., Lane D.P., and Fischer P.M. Mini-Rev. Med. Chem. 3 (2003) 257
5. Zhang W.H. Curr. Pharm. Des. 6 (2000) 393
6. Kojima K., Konopleva M., Samudio I.J., Shikami M., Cabreira-Hansen M., McQueen T., Ruvolo V., Tsao T., Zeng Z., Vassilev L.T., and Andreeff M. Blood 106 (2005) 3150
7. Vassilev L.T. Cell Cycle 3 (2004) 419
8. Klein C., and Vassilev L.T. Br. J. Cancer 91 (2004) 1415
9. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., and Liu E.A. Science 303 (2004) 844
10. Parks D.J., LaFrance L.V., Calvo R.R., Milkiewicz K.L., Gupta V., Lattanze J., Ramachandren K., Carver T.E., Petrella E.C., Cummings M.D., Maguire D., Grasberger B.L., and Lu T. Bioorg. Med. Chem. Lett. 15 (2005) 765
11. Grasberger B.L., Lu T., Schubert C., Parks D.J., Carver T.E., Koblish H.K., Cummings M.D., LaFrance L.V., Milkiewicz K.L., Calvo R.R., Maguire D., Lattanze J., Franks C.F., Zhao S., Ramachandren K., Bylebyl G.R., Zhang M., Manthey C.L., Petrella E.C., Pantoliano M.W., Deckman I.C., Spurlino J.C., Maroney A.C., Tomczuk B.E., Molloy C.J., and Bone R.F. J. Med. Chem. 48 (2005) 909
12. Koblish H.K., Zhao S., Franks C.F., Donatelli R.R., LaFrance L.V., Leonard K.A., Gushue J.M., Parks D.J., Calvo R.R., Milkiewicz K.L., Marugán J.J., Raboisson P., Cummings M.D., Grasberger B.L., Lu T., Molloy C.J., and Maroney A.C. Mol. Cancer Ther. 5 (2006) 160
13. Ghose A.K., Viswanadhan V.N., and Wendoloski J.J. J. Phys. Chem. A 102 (1998) 3762
14. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Adv. Drug Delivery Rev. 46 (2001) 3
15. Calculated using Pallas software version 3.21, CompuDrug Chemistry Ltd, San Fancisco, CA, USA.